Pfizer Inc. is entering 2023 with a full head of steam after announcing three applications for US FDA approval during the typically busy year-end period.
The company hopes to grow its vaccine portfolio with a pentavalent meningococcal vaccine that combines Pfizer’s Trumenba meningococcal group B...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?